Would you consider 177Lu-Dotatate (Lutathera) in patients with midgut neuroendocrine carcinoma after treatment with a somatostatin analog but with Ki67 >20%?   

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are within normal limits?

Answer from: Medical Oncologist at Academic Institution
Radiation Oncologist at East Alabama Medical Center
Thank you very much!
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice